Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
David Nather / Axios
A House panel quickly approved a bipartisan measure to speed the review of new generic drugs this morning, the first sign of congressional action this year to lower drug prices. The bill would require the FDA to conduct faster reviews of new generic drugs in markets where there's no competition, which would help address situations like the huge price increases for EpiPens. It was added to a larger measure that reauthorizes the user fees that help fund the FDA.
Why it matters: Republicans and Democrats don't agree on most ways to bring down drug prices, and Democrats on the committee have been pushing for a hearing on the issue. But encouraging more competition among generic drugs is fairly non-controversial solution that unites both parties.